European Consortium develops innovative test to predict the COVID-19 impact in the heart

A team led by CNC group leader Lino Ferreira integrates an European research consortium which seeks to develop a new diagnostic test to identify COVID-19 patients that may be prone to develop fatal cardiovascular complications.

Named “COVIRNA – A diagnostic test to ameliorate the surveillance and treatment of COVID-19 patients”, the project has a duration of 2 years, and has a 3.9 million euros worth of financing from the European Union, within the action plan ERavsCorona, which promotes the cooperation between European research institutions to strengthen the pandemic response.


News:

Diário de Coimbra | December 22 (see here)
Bairrada Informação Online | December 22 (see here)